![](/img/cover-not-exists.png)
1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC)
Vuylsteke, P., Huizing, M., Petrakova, K., Roylance, R., Laing, R., Chan, S., Abell, F., Apt, D., Zhou, J., Singel, S., Fehrenbacher, L.Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)30757-2
Date:
September, 2015
File:
PDF, 69 KB
english, 2015